Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)

Annamaria Iorio, Carlo Mario Lombardi, Claudia Specchia, Marco Merlo, Vincenzo Nuzzi, Ilenia Ferraro, Giulia Peveri, Chiara Oriecuia, Andrea Pozzi, Riccardo M. Inciardi, Valentina Carubelli, Antonio Bellasi, Claudia Canale, Rita Camporotondo, Francesco Catagnano, Laura Dalla Vecchia, Stefano Giovinazzo, Gloria Maccagni, Massimo Mapelli, Davide MargonatoLuca Monzo, Giovanni Provenzale, Filippo Sarullo, Daniela Tomasoni, Pietro Ameri, Massimiliano Gnecchi, Sergio Leonardi, Piergiuseppe Agostoni, Stefano Carugo, Gian Battista Danzi, Marco Guazzi, Maria Teresa La Rovere, Andrea Mortara, Massimo Piepoli, Italo Porto, Maurizio Volterrani, Gianfranco Sinagra, Michele Senni, Marco Metra

Research output: Contribution to journalArticlepeer-review


Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Patients admitted for acute coronary syndrome were excluded. Troponin levels were defined as elevated when greater than the 99th percentile of normal values. NPs were considered elevated if above the limit for ruling in acute heart failure (HF). A total of 341 patients were included in this study, mean age 68 ± 13 years, 72% were men. During a median follow-up period of 14 days, 81 patients (24%) died. In the Cox regression analysis, patients with elevated both NPs and troponin levels had higher risk of death compared with those with normal levels of both (hazard ratio 2.94; 95% confidence interval 1.31 to 6.64; p = 0.009), and this remained significant after adjustment for age, gender, oxygen saturation, HF history, and chronic kidney disease. Interestingly, NPs provided risk stratification also in patients with normal troponin values (hazard ratio 2.86; 95% confidence interval 1.21 to 6.72; p = 0.016 with high NPs levels). These data show the combined prognostic role of troponin and NPs in COVID-19 patients. NPs value may be helpful in identifying patients with a worse prognosis among those with normal troponin values. Further, NPs’ cut-point used for diagnosis of acute HF has a predictive role in patients with COVID-19.

Original languageEnglish
JournalAmerican Journal of Cardiology
Publication statusAccepted/In press - 2022

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)'. Together they form a unique fingerprint.

Cite this